Cardiff Oncology, Inc.

NasdaqCM:CRDF Stock Report

Market Cap: US$67.8m

Cardiff Oncology Management

Management criteria checks 2/4

Cardiff Oncology's CEO is Mani Mohindru, appointed in Jan 2026, has a tenure of less than a year. directly owns 0.086% of the company’s shares, worth $58.59K. The average tenure of the management team and the board of directors is 0.6 years and 12 years respectively.

Key information

Mani Mohindru

Chief executive officer

US$183.7k

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.09%
Management average tenureless than a year
Board average tenure12yrs

Recent management updates

Recent updates

Seeking Alpha • Jun 27

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Summary Cardiff Oncology's recent trial data readout delay has unnerved the market, but I see this as a potential buying opportunity for speculative investors. Leadership change is not a major risk factor. The new CMO's pedigree suggests confidence in the company's prospects ahead of the catalyst. The delay could suggest an attempt to improve poor data, or an ability to add to already strong data by waiting for more patient second scans. Short interest is high, increasing volatility and squeeze potential if trial data is strong, but also signaling caution from sophisticated investors. CRDF's cash runway is sufficient for the near-term catalyst; I hold call options expecting momentum to return, as the July 29th readout date approaches. Read the full article on Seeking Alpha
Analysis Article • May 21

Is Cardiff Oncology (NASDAQ:CRDF) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Feb 18

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Summary Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II results indicate superior efficacy in first-line treatment, supporting Cardiff's financial stability and long-term investment potential. The competitive landscape includes therapies like LUMAKRAS and KRAZATI, but Onvansertib's mutation-agnostic approach offers a unique advantage. Despite high risks, Cardiff's cash runway and positive clinical data justify a "Strong Buy" rating for high-risk tolerant long-term investors. Read the full article on Seeking Alpha
Seeking Alpha • Dec 12

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Summary Cardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising preliminary data, with improved response rates in a dose-dependent manner. Onvansertib appears well tolerated and effective when combined with standard chemotherapy and bevacizumab, but patient numbers remain low, necessitating further validation. Financially, CRDF's equity raise extends their cash runway, supporting the continued development and reducing immediate financial risk. Despite uncertainties, I maintain a Buy rating, anticipating onvansertib's potential to significantly impact first-line RAS-mutant mCRC therapy. Read the full article on Seeking Alpha
Seeking Alpha • Nov 07

Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next

Summary Cardiff Oncology's main focus is onvansertib, a PLK1 inhibitor, showing promise in metastatic colorectal cancer, especially in bevacizumab-naive patients. CRDF-004 phase 2 trial's results are crucial for Cardiff's future, with data expected within two months, potentially informing a pivotal phase 3 trial. Financially, Cardiff has a cash runway of 5-6 quarters, but will need additional funding, potentially leading to significant shareholder dilution. While optimistic about onvansertib's potential, I caution investors due to the high-risk nature and uncertain outcomes of the upcoming trial results. Read the full article on Seeking Alpha
Analysis Article • Oct 09

We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 04

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Summary Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated metastatic colorectal cancer, potentially opening a massive market with an estimated $567 million to $3.78 billion in annual US sales. Onvansertib has demonstrated superior efficacy and safety over historical controls and competitors, particularly in bevacizumab-naïve patients, with impressive objective response rates and progression-free survival. Positive data from the ongoing CRDF-004 trial could lead to significant upside for Cardiff, attracting potential partnerships or acquisition interest from big pharma, including Pfizer. Cardiff's strong financial position, low cash burn, and favorable analyst ratings make it a compelling buy, with substantial growth potential in the mCRC market and beyond. Read the full article on Seeking Alpha
Analysis Article • Jun 19

We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Mar 09

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Summary Cardiff Oncology is focused on developing a drug for colorectal cancer and pancreatic cancer, with promising early activity shown in colorectal cancer patients. The company is now focused on moving their drug to the first-line setting and has started a clinical trial to evaluate its efficacy. Cardiff Oncology has a strong financial position with enough funds to operate through Q3 2025, but the success of their drug is heavily dependent on the outcomes of a single trial. Read the full article on Seeking Alpha
Analysis Article • Mar 03

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 16

Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO

Mani Mohindru (54 yo)

less than a year
Tenure
US$183,670
Compensation

Dr. Mani Mohindru, Ph D., is Co-Founder, President and Director of Roshon Therapeutics. She had been Interim Chief Executive Officer at Cardiff Oncology, Inc. since January 27, 2026 until April 09, 2026 an...

Leadership Team

NamePositionTenureCompensationOwnership
Mani Mohindru
Presidentless than a yearUS$183.67k0.086%
$ 58.6k
Roger Sidhu
Chief Medical Officer1.2yrsUS$2.47m0%
$ 0
Josh Muntner
Chief Financial Officerless than a yearno data0.00073%
$ 495.1
Ajay Aggarwal
Chief Operating Officerless than a yearno datano data
Brigitte Lindsay
Chief Accounting Officerless than a yearno data0.040%
$ 27.2k
Tod Smeal
Chief Scientific Officer4.6yrsUS$4.17mno data
Elizabeth Anderson
VP of Finance & Administration11.1yrsno datano data
0.6yrs
Average Tenure
57yo
Average Age

Experienced Management: CRDF's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Mani Mohindru
President5.2yrsUS$183.67k0.086%
$ 58.6k
Charles Cantor
Member of Scientific Advisory Boardno datano datano data
Gary Pace
Independent Director6.3yrsUS$184.17k3.02%
$ 2.0m
K. Hirth
Member of Scientific Advisory Board12yrsno datano data
Paul Billings
Member of Scientific Advisory Board13.8yrsUS$35.85kno data
Rodney Markin
Independent Chairman of the Board12.5yrsUS$225.67k0.045%
$ 30.8k
Carlo Croce
Member of Scientific Advisory Boardno datano datano data
Riccardo Dalla-Favera
Member of Scientific Advisory Board16.3yrsno datano data
Lale White
Independent Director6.3yrsUS$189.17k0.17%
$ 112.9k
Alberto Bardelli
Member of Scientific Advisory Board11.9yrsno datano data
Renee Tannenbaum
Independent Director5.2yrsUS$181.67k0.029%
$ 19.8k
Brunangelo Falini
Member of Scientific Advisory Board16.3yrsno datano data
12.0yrs
Average Tenure
74yo
Average Age

Experienced Board: CRDF's board of directors are seasoned and experienced ( 12 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/09 16:14
End of Day Share Price 2026/08/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cardiff Oncology, Inc. is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Paul KnightBrean Capital Historical (Janney Montgomery)
Bryan BrokmeierCantor Fitzgerald & Co.
Gum-Ming LoweCraig-Hallum Capital Group LLC